ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00908154
Recruitment Status : Completed
First Posted : May 25, 2009
Last Update Posted : October 30, 2017
Sponsor:
Information provided by (Responsible Party):
Biogen

May 7, 2009
May 25, 2009
October 30, 2017
May 31, 2008
December 31, 2008   (Final data collection date for primary outcome measure)
  • Safety and tolerability will be evaluated by monitoring AEs and concomitant medication, ECG, Lead II monitoring, Holter monitoring, vital signs, and laboratory parameters. [ Time Frame: 14-28 days ]
  • Blood concentrations of GSK1014802 following a single oral dose of GSK1014802. [ Time Frame: 1 day ]
  • Blood concentrations of GSK1014802 following repeated oral doses of GSK1014802 given once daily or twice daily and their relationship with the GSK1014802 exposure after a single dose. [ Time Frame: 14-28 days ]
  • Blood concentrations of GSK1014802 following repeated oral doses of GSK1014802 given once daily with or without food. [ Time Frame: 14-28 days ]
Same as current
Complete list of historical versions of study NCT00908154 on ClinicalTrials.gov Archive Site
Bond-Lader VAS scale [ Time Frame: 14-28 days ]
Same as current
Not Provided
Not Provided
 
Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.
Single-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802 and Its Interaction With Food in Healthy Volunteers

GSK1014802 is a use-dependent sodium channel blocker and an effective anticonvulsant in animal models.

This study is being conducted to obtain information regarding the safety, tolerability and pharmacokinetics of repeated doses of GSK1014802 administered for up to 28 days in healthy male or female subjects. In addition, the effect of food on the pharmacokinetics of GSK1014802 will be investigated.

This study, previously posted by GlaxoSmithKline (GSK), was transitioned to Convergence Pharmaceuticals, Ltd., which spun off from GSK. Convergence Pharmaceuticals, Ltd., has now been acquired by Biogen.
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Bipolar Depression
  • Bipolar Disorder
  • Drug: Placebo
    Tablets to match GSK1014802
  • Drug: GSK1014802
    Sodium channel blocker
    Other Name: BIIB074 and CNV1014802
  • Cohort 1
    Interventions:
    • Drug: Placebo
    • Drug: GSK1014802
  • Cohort 4
    Interventions:
    • Drug: Placebo
    • Drug: GSK1014802
  • Cohort 3
    Interventions:
    • Drug: Placebo
    • Drug: GSK1014802
  • Cohort 2
    Interventions:
    • Drug: Placebo
    • Drug: GSK1014802
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
51
Same as current
December 31, 2008
December 31, 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.

    • Male or female (of non-child bearing potential) subjects aged between 18 and 55 years.
    • A female subject is eligible to participate if she is of non-childbearing potential.
    • Male subjects must agree to use an acceptable form of contraception.
    • Body weight ≥ 50 kg and BMI within the range 19 - 29.9 kg/m2 (inclusive)
    • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
    • QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.

Exclusion Criteria:

  • The subject has a positive pre-study drug/alcohol screen.

    • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
    • A positive test for HIV antibody.
    • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males), or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females).
    • Current or past history of symptomatic orthostatic hypotension or history of unexplained vasovagal episode(s).
    • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives (60 h) or twice the duration of the biological effect of the investigational product (whichever is longer).
    • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
    • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.
    • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
    • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
    • Pregnant females.
    • Lactating females.
    • Unwillingness or inability to follow the procedures outlined in the protocol.
    • History of sensitivity to heparin or heparin-induced thrombocytopenia.
    • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
    • . Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
    • History of known or suspected seizures, including infantile febrile, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits).
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT00908154
107727
SCB107727
Not Provided
Not Provided
Not Provided
Biogen
Biogen
Not Provided
Study Director: Biogen Medical Director Biogen
Biogen
October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP